Fabian Voß

JUST PUBLISHED @JACCJournals bit.ly/EuroTRScore See Online score EuroTR.eu Congrats @j_hausleiter @JennifervStein @KP_Kresoja @PhilippLurz @MariannaAdamo1 @Sticchi_Alex @JGrapsa @MarcoMetra @escardio @ACCinTouch

New🔥 #CSWG study: 🔑 messages: 1) most changes in clinical trajectories in CS patients occur within the first 6h of admission already (#goldenshift) ⏱️ 2) phenotyping and SCAI staging can be combined to improve risk stratification!🎯 sciencedirect.com/science/articl…

🔥 🔥 2 state of art 🗞️ on 📍 Non-amyloid specific 📍 Amyloid specific Treatments of #ATTR 🔍What you can do with the 4 pillars & more 🔬 From stabilizers to siRNA & gene editing 🧬 @HFUAcademy 🫀 👉bit.ly/4h3GFKq 👉bit.ly/4q7YThQ @ESC_Journals @ehj_ed @EJHFEiC @dr_pavia @MicheleEmdin @AlbertoAimo90 @IacopoOlivotto @glimongelli @DrMarthaGulati @stefanocarugo @ShelleyZieroth @scottdsolomon @DrRajivsankar @KTamirisaMD @mvaduganathan

🚨Recently Published in #CardioOncology Evaluation of a screening algorithm to detect cardiac amyloidosis in mild to severe aortic valve stenosis🫀 #OpenAccess Read more➡️doi.org/p7c4 @vofab @ICOSociety

#Wire-Based Interventional Clip Excision (WICE Procedure) to Allow Tran... sciencedirect.com/science/articl… 🔍 New #treatment approach for recurrent tricuspid regurgitation after #TEER! #TricuspidValve #TTVR #StructuralHeart #InterventionalCardiology #CardiologyResearch #AgPolzin

In this multicenter European registry, those patients in mid stage but not those in early or late stage of Tricuspid Regurgitation disease, showed significant 1-year survival with #TTEER vs conservative management. 4-parameter easy score to identify them. Thanks to the authors.

I’m honored to soon be serving on the steering committee of the CSWG alongside my fellow #cardiogenic #shock warriors, following the vision and leadership of @NavinKapur4 @BurkhoffMd @manreetkanwar @JHMontfort10 @ShashankSinhaMD and @ReshadGaranMD

Presented at #AHA24: In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo. Full trial results: nej.md/48OTgx4

🫀#RealWorldData on cardiac #amyloidosis treatment! 64% of #ATTRCM patients meet tafamidis trial criteria with treated patients showing higher #survival rates. High need for early detection🔥 Online: bit.ly/ESCHF_attrrwd @PiotrPonikowski #ATTR #HeartFailure #CardioTwitter

Original Article: Transcatheter Valve Replacement in Severe Tricuspid Regurgitation (TRISCEND II) nej.md/4dTODm5 Editorial: Early-Stage Results with Transcatheter Tricuspid-Valve Replacement nej.md/4e29F2f #TCT2024 | @crfheart

Congratulations to @ElricZweck, #JacobMoller and team for their late breaking work on #AKI in #AMICS at #TCT2024 with a simultaneous publication in @CircAHA - ahajournals.org/doi/10.1161/CI…. I had the privilege of writing the editorial comment ahajournals.org/doi/10.1161/CI…. @BrownUnivHealth

🚨­­ MAJOR news in the #ATTR #amyloidosis world! Today the ­­­much-anticipated HELIOS-B results were presented @escardio & simultaneously published in @NEJM. The largest ATTR-CM trial published to date, testing #vutrisiran vs. placebo. Bottom line: Huge win for vutrisiran! Lowered CV events and All-Cause mortality in the overall population & as monotherapy. Now, let’s take a deep dive into the results… nejm.org/doi/full/10.10…

A herculean #cardioonc effort amongst experts in assembling this statement on the rapidly evolving landscape of CV toxicities in cancer immunotherapeutics. Great resource to study more of what we don't know! 👏to colleagues and friends @ESC_Journals doi.org/10.1002/ejhf.3…

Thanks for sharing our latest publication @SN_Oncology and even more to the whole Team and all participating patients! @florian_bonner @RalfWestenfeld @cjungMD @DanielScheiber @SM_Haberkorn @amin_polzin

1/2 Following the DANGER SHOCK trial demonstrating reduced mortality with Impella in cardiogenic shock, the independent DSMB of the RECOVER IV trial has strongly recommended the trial be discontinued because of lack of equipoise. Therefore, we are ceasing enrollment in the trial.

We are proud to announce that the cardiology team at @UniklinikDUS successfully performed the first interventional transfemoral tricuspid valve replacement this week! A huge thank you to the entire team!

💥Happy to share publication of pilot phase of our German Cardiac Arrest Registry (G-CAR): link.springer.com/content/pdf/10… ➡️ next step: assessment of PROs 🙏 Thanks to all the investigators! #CardiacArrest #OHCA @DGK_AG3 @AnneFreund3 @thiele_holger @jochen_dutzmann @EPTIG

🔴 SGLT2 Inhibitor Therapy in Patients With TTR Amyloid Cardiomyopathy @JACCJournals #CardioEd #Cardiology #FOAMed #Amyloidosis

Happy to share our latest article discussing mitochondrias oxidative capacity in different subtypes of cardiac amyloidosis published by @JACCJournals ! @DanielScheiber @ElricZweck @RalfWestenfeld @amin_polzin

@ElricZweck @HarvardChanSPH @RalfWestenfeld @NavinKapur4 @MarcDonath Congrats! Well deserved!

Today, I received my diploma from ⁦@HarvardChanSPH⁩. Grateful for all the people whom I had the honor to meet on this journey and incredibly thankful to my mentors who have made it possible in the first place. ⁦@RalfWestenfeld⁩ ⁦@NavinKapur4⁩ ⁦@MarcDonath⁩